Home/Pipeline/CX-904

CX-904

Solid Tumors

Phase 1Active

Key Facts

Indication

Solid Tumors

Phase

Phase 1

Status

Active

Company

CytomX Therapeutics

About CytomX Therapeutics

CytomX Therapeutics is a clinical-stage oncology company leveraging its proprietary Probody® platform to develop conditionally activated therapeutics designed to minimize off-tumor toxicity. The company has built a diversified pipeline of eight candidates, including key clinical-stage assets like CX-904 (EGFRxCD3 T-cell engager) and CX-2051 (EpCAM ADC), supported by strategic partnerships with major pharmaceutical firms such as Amgen, AbbVie, and Bristol Myers Squibb. CytomX's strategy combines internal development of wholly-owned assets with a capital-efficient partnership model to validate and expand the application of its platform technology across multiple therapeutic modalities.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed